Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3: daclatasvir + peginterferon lambda-1a + ribavirin vs telaprevir + peginterferon alfa-2a + ribavirin in chronic hepatitis C genotype 1b
jRCT2080222042Phase 3
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of daclatasvir in chronic hepatitis C (CHC) (2 arms), sponsored by Bristol Myers Squibb.
02
Drugs
daclatasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on jRCT2080222042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222042.